Inveox develops an integral IoT/SaaS system combining a lab automation machine, an intelligent sample container, and AI-enhanced software to digitize and automate histopathology workflows. The company aims to increase safety and reliability of cancer diagnoses while improving lab efficiency and enabling data-driven personalized diagnostics. Founded in 2017 and based in Munich, inveox has entered the DACH market and opened a subsidiary office in Krakow, Poland. The startup is implementing its system with several customers in the DACH region, including university clinics in Germany. With its largest investment to date, the company plans to begin series-level production of its automation system and expand into further markets later this year. Inveox has participated in accelerator programs and won awards, including Roche Diagnostics/Plug&Play Digital Health and EIT Health, and was selected for the Texas Medical Center Accelerator program.

Total raised

$19M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2019